We are one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.
Our products range from active ingredients, through tablets and injections, to galenic (i.e. liquid and semi-solid) formulations and are available in 62 countries in total through our network of subsidiaries and representative offices or partners. Last financial year our portfolio consisted of 642 products that belonged to 166 product lines and contained 149 active ingredients.
Our main focus lies in treating diseases of the cardiovascular and central nervous systems; however, we also provide modern treatment solutions in the fields of oncology and women’s health. In 2013, we launched our first biosimilar monoclonal antibody product. This was also the first biosimilar monoclonal antibody (mAb) in the European Union. Since then we launched three additional biosimilar drugs.